Short answer
Kymera Therapeutics, Inc. (KYMR) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Quarterly results announced for period ended September 30, 2026.
Kymera Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Quarterly results announced for period ended September 30, 2026
- Full financial details and management commentary in Exhibit 99.1
- Information furnished under Regulation FD, limiting Section 18 liability absent specific incorporation by reference
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 net loss $132.0M, or $1.32 per share, versus $82.2M, reflecting sharply higher pipeline investment
- R&D expense $128.5M, up from $74.1M, primarily supporting STAT6, discovery programs and organizational growth
- KT-579 achieved ≥90% median IRF5 degradation and biomarker suppression of 88%-98%, supporting lupus Phase 1b launch by early 2027
- KT-621 BROADEN2 AD topline data expected by year-end 2026, with Phase 3 initiation targeted for mid-2027
- Cash, equivalents and investments $1.6B, providing runway into 2029 across multiple clinical inflection points
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kymera Therapeutics, Inc. 8-K filings
Get the next KYMR 8-K as it lands
Follow KYMR for push alerts, or ask the research agent what this filing means.